Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (12153)	6/24/2004 12:01:35 PM
From: Biomaven	Respond to of 52153

<KOSN> The way they describe the problem "cumulative drug toxicities in patients who had been previously treated with oxaliplatin" leads me to believe that it was a problem with sensory neuropathy. Cumulative sensory neuropathy is the limiting toxicity of oxaliplatin by itself, and my guess is that epo simply added to this. If this is correct, it doesn't impact the issue of using epo in patients that haven't been heavily pre-treated with oxaliplatin. Peter